Securities Code: 301096
Securities Abbreviation: Bio-Cheng Pharmaceutical
Announcement No.: 2026-036
Hangzhou Bio-Cheng Pharmaceutical Technology Co., Ltd.
Announcement on the Notification of Clinical Trial Approval for Innovative Drug BIOS0635-048 Tablets
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
Hangzhou Bio-Cheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") recently learned that its self-developed innovative drug BIOS0635-048 Tablets has received a clinical trial approval notification from the National Medical Products Administration (NMPA).
The situation is hereby announced as follows:
I. Basic Information of the Drug